Metformin use among individuals at risk for type 2 diabetes

Current Diabetes Reports

Volumn 12, Issue 3, 2012, Pages 265-273

  Kuller, Lewis H ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cancer, prevention; Coronary heart disease; Insulin; Metformin; Obesity; Screening; Type 2 diabetes

Indexed keywords

ANTILIPEMIC AGENT; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN;

ARTERIOSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; BARIATRIC SURGERY; CELL STRESS; DIET RESTRICTION; DIET THERAPY; DRUG COST; DRUG MECHANISM; DRUG SAFETY; DRUG USE; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LACTIC ACIDOSIS; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; RISK ASSESSMENT; RISK REDUCTION;

ATHEROSCLEROSIS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; EARLY DIAGNOSIS; FASTING; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; METFORMIN; OBESITY; RISK FACTORS; TREATMENT OUTCOME;

EID: 84861098928     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-012-0263-x     Document Type: Article

References (94)

1. Lean M. Health consequences of overweight and obesity in adults. In: Jeffery RW, Ball K, Brug J, editors. Obesity epidemiology from aetiology to public health. 2nd ed. New York: Oxford University Press; 2010. p. 43-58.
2. Guerrero R, Vega GL, Grundy SM, Rowning JD. Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatol. 2009;49:791-801.
3. Trujillo ME, Scherer PE. Adipose tissue-derived factors: impact on health and disease. Endocr Rev. 2006;27:762-78. (Pubitemid 44936059)
4. Mackey RH, Chang Y-FM, Tinker LF, et al. Lipoprotein particles predict incident coronary heart disease among extremely obese (BMI greater than or equal to 40) black and white postmenopausal women. Presented at the 50th Cardiovascular Disease Epidemiology and Prevention Scientific Sessions 2010. March 3-5, 2010, San Francisco, CA.
5. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860-7. (Pubitemid 46024993)
6. Olefsky J, Glass C. Macrophages, inflammation and insulin resistance. Annu Rev Physiol. 2010;72:1-28.
7. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773-95.
8. Paynter NP, Mazer NA, Pradhan AD, et al. Cardiovascular risk prediction in diabetic men and women using hemoglobin A1c vs. diabetes as a high risk equivalent. Arch Intern Med. 2011;171:1712-8.
9. Saad MF, Knowler WC, Pettitt DJ, et al. Sequential changes in serum insulin concentration during development of non-insulindependent diabetes. Lancet. 1989;1:1356-9. (Pubitemid 19151955)
10. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? Arch Intern Med. 2004;164:2147-55.
11. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332:1519-23.
12. Ndumele CE, Nasir K, Conceicao RD, et al. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler Thromb Vasc Biol. 2011;31:1927-32.
13. Crawford JM, Cotran RS. The pancreas. In: Cotran RS, Kumar V, Collins T, editors. Pathologic basis of disease. Philadelphia: WB Saunders Company; 1999. p. 902-29.
14. Kelly TN, Bazzano LA, Fonseca VA, et al. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med. 2009;151:394-403.
15. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-39.
16. Reaven PD, Mortiz TE, Schwenke DC, et al. Intensive glucoselowering therapy reduces cardiovascular disease events in Veterans Affairs Diabetes Trial participants with lower calcified coronary atherosclerosis. Diabetes. 2009;58:2642-8.
17. Olafsdottir E, Aspelund T, Sigurdsson G, et al. Unfavourable risk factors for type 2 diabetes mellitus are already apparent more than a decade before onset in a population-based study of older persons: from the age, Gene/Environment Susceptibility-Reykjavik Study (AGES-Reykjavik). Eur J Epidemiol. 2009;24:307-14.
18. Vliegenthart R. Non-invasive assessment of coronary calcification. Eur J Epidemiol. 2004;19:1063-72. (Pubitemid 40228494)
19. Raggi P, Shaw LJ, Berman DS, Callister TQ. Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol. 2004;43:1663-9. (Pubitemid 38561350)
20. Kuller LH, Velentgas P, Barzilay J, et al. Diabetes mellitus: subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality. Arterioscler Thromb Vasc Biol. 2000;20:823-9. (Pubitemid 30151699)
21. Spencer EA, Pirie KL, Stevens RJ, et al. Diabetes and modifiable risk factors for cardiovascular disease: the prospective Million Women Study. Eur J Epidemiol. 2008;23:793-9.
22. Peralta CA, Adeney KL, Shlipak MG, et al. Structural and functional vascular alterations and incident hypertension in normotensive adults. The Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol. 2010;171:63-71.
23. Duprez DA, Jacobs Jr. DR, Lutsey PL, et al. Association of small artery elasticity with incident cardiovascular disease in older adults. The Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol. 2011;174:528-36.
24. Kuller LH, Margolis KL, Gaussoin SA, et al. Relationship of hypertension, blood pressure, and blood pressure control with white matter abnormalities in the Women's Health Initiative Memory Study (WHIMS)-MRI trial. J Clin Hypertens. 2010;12:203-12.
25. Wilkinson IB, McEniery CM, Cockcroft JR. Arteriosclerosis and atherosclerosis. Hypertension. 2009;54:1213-5.
26. Laurent S, Briet M, Boutouyrie P. Large and small artery cross-talk and recent morbidity-mortality trials in hypertension. Hypertension. 2009;54:388-92.
27. Bowler JV, Gorelick PB. Advances in vascular cognitive impairment. Stroke. 2009;40:e315-8.
28. Lambers Heerspink HJ, Holtkamp FA, de Zeeuw D, Ravid M. Monitoring kidney function and albuminuria in patients with diabetes. Diabetes Care. 2011;34:S325.
29. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65:2309-20. (Pubitemid 38670018)
30. Lloyd-Jones DM, Leip Ep, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113:791-8.
31. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238:467-85. (Pubitemid 38176385)
32. Rubino F, Schauer PR, Kaplan LM, Cummings DE. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med. 2010;61:393-411.
33. Cummings DE, Overduin J, Foster-Schubert KE, Carlson MJ. Role of the bypassed proximal intestine in the anti-diabetic effects of bariatric surgery. Surg Obes Relat Dis. 2007;3:109-15. (Pubitemid 46444709)
34. Thaler JP, Cummings DE. Minireview: hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology. 2009;150:2518-25.
35. Sjostrom L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307:56-65.
36. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683-93. (Pubitemid 39665322)
37. Renehan AG. Bariatric surgery, weight reduction, and cancer prevention. Lancet Oncol. 2009;10:640-1.
38. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81.
39. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117-25.
40. Nicholls SJ, Tuzcu M, Kalidindi S, et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling. J Am Coll Cardiol. 2008;52:255-62.
41. Nicolucci A, Standl E. Antiplatelet therapy for every diabetic person? Diabetes Care. 2011;34:S150-4.
42. Prisant ML, Louard RJ. Controversies surrounding the treatment for the hypertensive patient with diabetes. Curr Hypertens Rep. 1999;1:512-20.
43. Hansson L. The Hypertensive Optimal Treatment Study and the importance of lowering blood pressure. J Hypertens. 1999;17:S9-S13. (Pubitemid 29116663)
44. Lepor NE. Key findings from the 2007 European Society of Cardiology Congress. Rev Cardiovasc Med. 2007;8:220-7.
45. Kahn HS, Cheng YJ, Thompson TJ, et al. Two risk-scoring systems for predicting incident diabetes mellitus in U.S. adults age 45 to 64 years. Ann Intern Med. 2009;150:741-51.
46. Walford GA, Florez JC. Type 2 diabetes and genetics, 2010: translating knowledge into understanding. Curr Cardiol Risk Rep. 2010;4:437-45.
47. Koskinen J, Kahonen M, Viikari JSA, et al. Conventional cardiovascular risk factors and metabolic syndrome in predicting carotid intima-media thickness progression in young adults. The Cardiovascular Risk in Young Finns Study. Circulation. 2009;120:229-36.
48. Juonala M, Magnussen CG, Berenson GS, et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med. 2011;365:1876-85.
49. Daniels SR, Pratt CA, Hayman LL. Reduction of risk for cardiovascular disease in children and adolescents. Circulation. 2011;124:1673-86.
50. Gray L, Lee I-M, Batty GD. Body weight in early and midadulthood in relation to subsequent coronary heart disease mortality: 80-year follow-up in the Harvard Alumni Study. Arch Intern Med. 2011;171:1768-70.
51. Ma J, Flanders WD, Ward EM, Jemal A. Body mass index in young adulthood and premature death: analyses of the US National Health Interview Survey linked mortality files. Am J Epidemiol. 2011;174:934-44.
52. Preis SR, Hwang S-J, Coady S, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. 2009;119:1728-35.
53. Fox CS, Coady S, Sorlie PD, et al. Trends in cardiovascular complications of diabetes. JAMA. 2004;292:2495-9. (Pubitemid 39552675)
54. American Diabetes Association. Clinical practice recommendations 2011. Diabetes Care. 2011;34:S1-S98.
55. Schottker B, Raum E, Rothenbacher D, et al. Prognostic value of haemoglobin A1c and fasting plasma glucose for incident diabetes and implications for screening. Eur J Epidemiol. 2011;26:779-87.
56. Rhee MK, Herrick K, Ziemer DC, et al. Many Americans have pre-diabetes and should be considered for metformin therapy. Diabetes Care. 2010;33:49-54.
57. The Emerging Risk Factors Collaboration. Diabetes, mellitus, fasting glucose, and risk of cause-specific death. N Eng J Med. 2011;364:829-41.
58. BlahaMJ, DeFilippis AP, Rivera JJ, et al. The relationship between insulin resistance and incidence and progression of coronary artery calcification. Diabetes Care. 2011;749-51.
59. Yeboah J, Bertoni AG, Herrington DM, et al. Impaired fasting glucose and the risk of incident diabetes mellitus and cardiovascular events in an adult population. MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2011;58:140-6.
60. Kendall DM. The dyslipidemia of diabetes mellitus: giving triglycerides and high-density lipoprotein cholesterol a higher priority? Endocrinol Metab Clin N Am. 2005;34:27-48. (Pubitemid 40332501)
61. Hirst JA, Farmer AJ, Ali R, et al. Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care. 2012;35:446-54.
62. DeFronzo RA, Goodman AM, the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulindependent diabetes mellitus. N Engl J Med. 1995;333:541-9.
63. Saenz A, Fernandez-Esteban I, Mataix A, et al. Metformin monotherapy for type 2 diabetes mellitus (review). Cochrane Database Syst Rev. 2005;20(3):CD002966.
64. UK Prospective Diabetes Study (UKPDS) Study Group. Effective intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-65.
65. Herman WH, Edelstein SL, Ratner RE, et al. The 10-year costeffectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes mellitus: an intent-to-treat analysis of diabetes prevention (Abstract No. 0136-LBOR). Diabetes. 2011;60:A1-A104.
66. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
67. Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program outcomes study. Lancet. 2009;374:1677-86.
68. Grant P. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care. 1996;19:64-6.
69. Eleftheriadou I, Grigoropoulou P, Katsilambros N, Tentolouris N. The effects of medications used for the management of diabetes and obesity on postprandial lipid lowering metabolism. Curr Diabetes Rev. 2008;4:340-56.
70. Correia S, Carvalho C, Santos MS, et al. Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview. Mini Rev Med Chem. 2008;8:1343-54.
71. El Messaoudi S, Rongen GA, de Boer RA, Riksen NP. The cardioprotective effects of metformin. Curr Opin Lipidol. 2011;22:445-53.
72. Chong CR, Chabner BA. Mysterious metformin. Oncologist. 2009;14:1178-81.
73. Micic D, Cvijovic G, Trajkovic V, et al. Metformin: its emerging role in oncology. Horm. 2011;10:5-15.
74. Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer. A cohort study among people with type 2 diabetes. Diabetes Care. 2009;32:1620-5.
75. Lee M-S, Hsu C-C, Wahlqvist ML, et al. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 2011;11:20.
76. Anisimov VN, Piskunova TS, Popovich IG, et al. Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice. Aging. 2010;2:945-58.
77. Anisimov VN, Berstein LM, Popovich IG, et al. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging. 2011;3:148-57.
78. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310:1642-6. (Pubitemid 41780780)
79. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus (review). Cochrane Database Syst Rev. 2010;14(4): CD002967.
80. Misbin RI. The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care. 2004;27:1791-3. (Pubitemid 38857465)
81. Going SB, Lohman TG, Cussler EC, et al. Percent body fat and chronic disease risk factors in U.S. children and youth. Am J Prev Med. 2011;41:S77-86.
82. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-93. (Pubitemid 36159355)
83. Fonseca VA. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus. Am J Med. 2007;120:S18-25. (Pubitemid 47361039)
84. Liu J, Fox CS, Hickson D, et al. Fatty liver, abdominal visceral fat, and cardiometabolic risk factors. The Jackson Heart Study. Arterioscler Thromb Vasc Biol. 2011;31:2715-22.
85. Czernichow S, Kengne A-P, Stamatakis E, et al. Body mass index, waist circumference and waist-hip ratio: which is the better discriminator of cardiovascular disease mortality risk? evidence from an individual-participant meta-analysis of 82,864 participants form nine cohort studies. Obes Rev. 2011;12:680-7.
86. Meigs JB, Larson MG, D'Agostino RB, et al. Coronary artery calcification in type 2 diabetes and insulin resistance. Diabetes Care. 2002;25:1313-9. (Pubitemid 41071138)
87. McEvoy JW, Blaha MJ, DeFilippis AP, Budoff MJ, et al. Coronary artery calcium progression: an important clinical measurement? J Am Coll Cardiol. 2010;56:1613-22.
88. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31-40.
89. Spencer MS, Rosland A-M, Kieffer EC, et al. Effectiveness of a community health worker intervention among African American and Latino adults with type 2 diabetes: a randomized controlled trial. Am J Public Health. 2011;101:2253-60.
90. DeRekeneire N, Rooks RN, Siminsick EM, et al. Racial differences in glycemic control in a well-functioning older diabetic population. Diabetes Care. 2003;26:1986-92.
91. American Diabetes Association. Third-party reimbursement for diabetes care, self-management education, and supplies. Diabetes Care. 2011;33:S87-8.
92. Norris SL, Zhang X, Avenell A, et al. Long-term non-pharmacological weight loss interventions for adults with prediabetes (review). Cochrane Database Syst Rev. 2005;18:CD005270.
93. Vega GL. Cardiovascular outcomes for obesity and metabolic syndrome. Obes Res. 2002;10:27S.
94. Rubino F, Kaplan LM, Schauer PR, Cummings DE, on behalf of the Diabetes Surgery Summit Consensus Conference. Recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg. 2010;251:399-405.